Alvespimycin

Alvespimycin has been studied in 7 papers since 2017: none in people yet, 5 in animals, 1 in cells, 1 review. The research so far is in animals and cells. The newest paper, Dec 4, 2024: “Design of a Magnetic Nanoplatform Based on CD26 Targeting and HSP90 Inhibition for Apoptosis and Ferroptosis-Mediated Elimination of Senescent Cells”.

InterventionPhase 2

7 papers study it2 findingsUpdated

PubChemChEBI

See all 7 papers on alvespimycin

At a glance

The findings reach mice, none yet in people. 1 lab in 1 country; 7 trials, none about aging, 6 with no results posted.

None of its findings points the other way.

Mice: a single group. Cells, worms or flies and humans: nothing yet.
  • 1 lab in 1 country
  • 7 trials, none about aging, 6 with no results posted
  • Funders: Diabetes Australia and 2 more
  • Animals5
  • Cells1

What did mouse lifespan tests of alvespimycin find?

NIA ITP

The NIA Interventions Testing Program ran 1 arm in 2015; the change in median lifespan ran from −4% to +9%.

What did studies of alvespimycin find?

2

Studies of alvespimycin measured 2 outcomes: tubulointerstitial fibrosis and cellular senescence.

Tubulointerstitial fibrosis

downin mice1

1 study
  1. Alvespimycin decreases tubulointerstitial fibrosis in diabetic mice following acute kidney injury.

    “Treatment with alvespimycin alone reduced kidney senescence and levels of Col1a1, Acta2, Tgfb1, and Cd68”

    Animalsin diabetic mice following acute kidney injurykidney

    Intervention treatment reducing cellular senescence inhibits tubulointerstitial fibrosis in diabetic mice following acute kidney injury

    Clinical science (London, England : 1979)

More on Tubulointerstitial fibrosis

Cellular senescence

downin mice1

1 study
  1. Alvespimycin decreases cellular senescence in diabetic mice following acute kidney injury.

    “Treatment with alvespimycin alone reduced kidney senescence and levels of Col1a1, Acta2, Tgfb1, and Cd68”

    Animalsin diabetic mice following acute kidney injurykidney

    Intervention treatment reducing cellular senescence inhibits tubulointerstitial fibrosis in diabetic mice following acute kidney injury

    Clinical science (London, England : 1979)

More on Cellular senescence

Has alvespimycin been tested in people?

0 of 7 about aging

7 trials are registered, but no study of it in people has been published yet.

In trials

All 23

Stopped

  • NCT01126502TerminatedLeukemia, Lymphocytic, Chronic, B-Cell

    Administratively Complete.

Trial sponsors

Latest